α2 Macroglobulin and the risk of Alzheimer's disease

Neurology

Volumn 54, Issue 2, 2000, Pages 438-442

  Dodel, R C ^a   Du, Yansheng ^a   Bales, K R ^b   Gao, F ^a   Eastwood, B ^b   Glazier, B ^a   Zimmer, R ^g   Cordell, B ^f   Hake, A ^a   Evans, R ^a   Gallagher Thompson, D ^c   Thompson, L W ^c   Tinklenberg, J R ^c,d   Pfefferbaum, A ^e   Sullivan, E V ^c   Yesavage, J ^c,d   Altstiel, L ^b   Gasser, T ^h   Farlow, M R ^a   Murphy Jr , G M ^c   Paul, S M ^b   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e SRI INTERNATIONAL   (United States)

^f SCIOS INC   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

AD; Apolipoprotein E; Polymorphism; 2 Macroglobulin

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE DELETION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; UNIVERSITY HOSPITAL; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; RISK; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; ALZHEIMER DISEASE; APOLIPOPROTEINS E; EXONS; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0034711619     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.54.2.438     Document Type: Article

References (35)

1. Roses AD. Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am J Med Genet 1998;81:49-57.
2. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321-322.
3. Kamboh MI, Sanghera DK, Ferrell RE, et al. APOE*4-associated Alzheimer's disease risk is modified by α 1-anti-chymotrypsin polymorphism. Nat Genet 1995;104:486-488.
4. Hollenbach E, Ackermann S, Hyman BT, et al. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. Neurology 1998;50:1905-1907.
5. Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease: Alzheimer's Disease Collaborative Group. Lancet 1996;347:509-512.
6. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 1998;18:69-71.
7. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease: evidence for a new locus on chromosome 12. JAMA 1998;278: 1237-1241.
8. Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360.
9. Liao A, Nitsch RM, Greenberg SM, et al. Genetic association of an alpha 2-macroglobulin polymorphism and Alzheimer's disease. Hum Mol Genet 1998;7:1953-1956.
10. Borth W. α2-Macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 1992;6:3345-3353.
11. Rebeck GW, Harr SD, Strickland DK, et al. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995; 37:211-217.
12. Back SA, Alhadeff JA. Differential isoform profiles of alpha 2-macroglobulin from plasma of patients with chronicprogressive or relapsing-remitting multiple sclerosis. Clin Chim Acta 1992;211:27-36.
13. Bauer J, Ganter U, Jonas U, et al. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992;66:223-230.
14. 2-Macroglobulin as an Amyloid β peptide binding plasma protein. J Neurochem 1997;69:299-305.
15. 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem 1998;70:1182-1188.
16. Hughes SR, Khorkova O, Goyal S, et al. α2-Macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 1998;95:3275-3280.
17. Qiu WQ, Borth W, Ye Z, et al. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem 1996;271:8443-8451.
18. Narita M, Holtzman DM, Schwartz AL, Bu G. α2-Macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 1997;69:1904-1911.
19. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I: clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-1165.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1988;34:939-944.
21. World Health Organization. The ICD-10 Classification of mental and behavioral disorders: diagnostic criteria for research. Geneva: Author, 1992.
22. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812.
23. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J. Age-specific norms for the Mini-Mental State Examination. Neurology 1988;38:1565-1568.
24. Kessler J, Markowitsch HJ, Denzler PE. "Mini-Mental State." Deutsche Fassung. Weinheim, Germany: Beltz-Verlag, 1990.
25. Kurz A, Altland K, Lautenschlager N, et al. Apolipoprotein E type 4 allele and Alzheimer's disease: effect on age at onset and relative risk in different age groups. J Neurol 1996;243: 452-456.
26. Murphy GM Jr, Sullivan EV, Gallagher-Thompson D, et al. No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Neurology 1997;48:1313-1316.
27. Dodel RC, Bales KR, Farlow MR, et al. Rapid detection of a pentanucleotide deletion polymorphism in the human α2-macroglobulin gene. Clin Chem 1999;45:307-317.
28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
29. Dupont WD. Power calculations for matched case-control studies. Biometrics 1988;44:1157-1168.
30. Breslow NE, Day NE. Statistical methods in cancer research, vol. 1: the analysis of case-control studies. Lyon, France: IARC, 1980.
31. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA 1997; 278:1349-1356.
32. Rudrasingham V, Wavrant-DeVrièze, Lambert JC, et al. α2 Macroglobulin gene and Alzheimer disease. Nat Genet 1999; 22:17-19.
33. Dow DJ, Lindsey N, Cairns NJ, et al. α-2 Macroglobulin polymorphism and Alzheimer disease risk in the UK. Nat Genet 1999;22:16-17.
34. Rogaeva EA, Premkumar S, Scott WK, et al. An α-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet 1999;22:19-21.
35. Daly MJ. Untangling the genetics of a complex disease. JAMA 1998;280:652-653.